We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Bipolar RF Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue and Effect on Elastin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04245696
Recruitment Status : Withdrawn (Business decision, no serious AEs.)
First Posted : January 29, 2020
Last Update Posted : August 6, 2021
Information provided by (Responsible Party):
Candela Corporation

Brief Summary:
This study is being conducted to evaluate the safety and efficacy of bipolar fractional radiofrequency treatment via use of the Profound System to achieve lift in lax submental (beneath the chin) and neck tissue

Condition or disease Intervention/treatment Phase
Skin Laxity Device: Dermal Handpiece / SubQ Handpiece Not Applicable

Detailed Description:

A multi-center, blinded, non-randomized, non-controlled study

Up to 60 eligible participants will be enrolled at up to three (3) sites. Participants will receive one (1) treatment in the submental/neck area. Participants will complete follow-up visits for clinical evaluation at Day 14, 1 Month, 3 Month, and 6 Months after the study treatment. Standard photography will be obtained at Screening to the 6 Month follow-up, and 3D photography will be obtained at Screening, Month 3, and Month 6 visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue
Actual Study Start Date : March 9, 2020
Actual Primary Completion Date : August 5, 2021
Actual Study Completion Date : August 5, 2021

Arm Intervention/treatment
Experimental: Single Group
Single Arm: All subjects will undergo treatment for skin laxity in the submentum with a Dermal and SubQ handpiece
Device: Dermal Handpiece / SubQ Handpiece
Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.

Primary Outcome Measures :
  1. Change in submental skin laxity [ Time Frame: Baseline - Day 180 (6 months post-treatment) ]
    Improvement in overall lifting of treated tissue in the submental/neck region via blinded evaluation of Baseline (pre-procedure) and Day 180 (post-procedure) photographs

  2. Occurrence, severity, and relatedness of adverse events [ Time Frame: Baseline - Day 180 (6 months post-treatment) ]
    The number and level of severity of adverse events after device treatment. An assessment will also be made to determine if the adverse event is related to the study devices and/or procedure

Secondary Outcome Measures :
  1. Change in submental skin laxity [ Time Frame: Baseline - Day 90 (3 months post-treatment) ]
    Improvement in overall lifting of treated tissue in the submental/neck region via blinded evaluation of Baseline (pre-procedure) and Day 90 (post-procedure) photographs

  2. Surface Area Assessment to demonstrate percentage of participants having improvement in tissue lift (> 20mm2 in submental and neck skin laxity) [ Time Frame: Baseline vs. Day 180 ]
    Change in submental and neck skin laxity via 3D photo-analysis

  3. Subject assessment of improvement in skin laxity [ Time Frame: 3 Month Follow-Up and 6 Month Follow-Up ]
    Improvement in skin laxity scored by subject using a 5-point Global Aesthetic Improvement Score (1=Very Much Improved, 5=Worse)

  4. Subject satisfaction of treatment results: Subject Satisfaction scale [ Time Frame: Day 14 - 6 Month Follow-Up ]
    Using a Subject Satisfaction scale, subjects will score satisfaction of treatment results (1=Not Satisfied, 5=Very Satisfied). Lower scores will show worse outcomes and higher scores will show better outcomes.

  5. Subject assessment of pain: Numerical Pain Rating Scale [ Time Frame: Treatment Visit ]
    The subjects' assessment of pain will be completed using an 11-point Numerical Pain Rating Scale (0=No pain, 10=extreme pain)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male and female adults between ages 21-70 years of age.
  • Desire skin laxity lift of submental and neck regions.
  • Confirmed BMI ≤ 35.
  • Subjects who can read, understand, and sign the Informed Consent Form.
  • Subjects willing and able to comply with all study requirements.
  • Fitzpatrick skin type I-VI.
  • Submental fat graded by the Investigator as ≥ 1 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS, 0=Absent (No localized submental fat evidence), 4=Extreme (Extreme submental convexity)

Exclusion Criteria:

  • Active localized or systemic infections, that may alter wound healing.
  • Immunocompromised subjects.
  • Subjects with coagulation disorder.
  • History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs).
  • Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study).
  • Excessive skin laxity on the submental and neck (Submental Skin Laxity Grade: SMSLG 4=Severe, superficial wrinkling present), or other anatomical feature for which reduction in submental fat (SMF) which may, in the judgment of the investigator, result in an aesthetically unacceptable outcome.
  • Scarring in areas to be treated.
  • Tattoos in the treatment areas to be treated.
  • Significant open facial wounds or lesions.
  • Severe or cystic acne in treatment areas.
  • Current active smoker.
  • Use of Accutane (Isotretinoin) within the past 6 months.
  • Use of topical retinoids within 48 hours.
  • Use of prescription anticoagulants.
  • Pacemaker or internal defibrillator.
  • History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin).
  • Subjects on current oral corticosteroid therapy or within the past 6 months
  • Metal implants in the treatment area.
  • In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits.
  • Subjects with a history of radiation therapy to the treatment area.
  • Subject has a history of allergy to lidocaine or ester-based local anesthetics.
  • Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine.
  • Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation).
  • Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator.
  • Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year.
  • Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area.
  • Subjects have undergone laser and light treatments in the treatment area over the past 3 months.
  • Subjects have undergone superficial peel or microdermabrasion within 4 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04245696

Layout table for location information
United States, Massachusetts
Candela Institute of Excellence
Marlborough, Massachusetts, United States, 01752
Sponsors and Collaborators
Candela Corporation
Layout table for investigator information
Principal Investigator: Konika Patel Schallen, MD Candela Medical
Layout table for additonal information
Responsible Party: Candela Corporation
ClinicalTrials.gov Identifier: NCT04245696    
Other Study ID Numbers: PFD19002
First Posted: January 29, 2020    Key Record Dates
Last Update Posted: August 6, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Candela Corporation:
Submental Skin Laxity
Additional relevant MeSH terms:
Layout table for MeSH terms
Cutis Laxa
Skin Diseases, Genetic
Genetic Diseases, Inborn
Connective Tissue Diseases
Skin Diseases